E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series
Hind Rafei,Elias Jabbour,Hagop M. Kantarjian,Kaylyn D Sinicrope,Carlos Kamiya-Matsuoka,Rohtesh S. Mehta,Naval Daver,Tapan M. Kadia,Kiran Naqvi,Jorge E. Cortes,Marina Konopleva +10 more
TL;DR: This research presents a novel and scalable approach that combines cell reprograming and “cell reprogramming” which has the potential to improve the quality of life of patients undergoing stem cell transplantation.
Journal ArticleDOI
A Patient-Reported Outcome Measure for Symptoms and Symptom Burden of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Loretta A. Williams,Araceli Garcia-Gonzalez,Hycienth Ahaneku,Jorge E. Cortes,Guillermo Garcia-Manero,Hagop M. Kantarjian,Tito R. Mendoza,Qiuling Shi,Gautam Borthakur,Jan A. Burger,Elias Jabbour,Koichi Takahashi,Huei K. Lin,Achala Limaye,Charles S. Cleeland +14 more
TL;DR: The MDASI-AML/MDS is a brief, easily-completed, and validated measure of symptom burden for patients with AML and MDS that can be used for accurate and consistent monitoring of symptoms by clinicians and researchers.
Journal ArticleDOI
New agents in myelodysplastic syndromes.
Elias Jabbour,Francis J. Giles +1 more
TL;DR: Novel and targeted therapeutic agents such as the inhibition of farnesyltransferases and receptor tyrosine kinases, more potent thalidomide analogs, arsenic trioxide, immunomodulating agents, hypomethylating agents, and histone deacetylase inhibitors have shown encouraging results and may offer durable benefit to patients with MDS.
Journal ArticleDOI
A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia
Nicholas J. Short,Hagop M. Kantarjian,Elias Jabbour,Jorge E. Cortes,Deborah A. Thomas,Michael Rytting,Naval Daver,Yesid Alvarado,Marina Konopleva,Partow Kebriaei,William G. Wierda,Courtney D. DiNardo,Carol Bivins,Deborah McCue,Mary Ann Richie,Farhad Ravandi +15 more
TL;DR: Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukesin 10 in von Willebrand disease are studied.
Journal ArticleDOI
Relapsed B‐acute lymphoblastic leukemia with aberrant myeloperoxidase expression following CAR T‐cell therapy: A diagnostic challenge
Nianyi Li,Sa A. Wang,Pei Lin,Elias Jabbour,Philip A. Thompson,Zhining Chen,Shaoying Li,Jie Xu,M. James You,Carlos E. Bueso-Ramos,L. Jeffrey Medeiros,C. Cameron Yin +11 more
TL;DR: An 18-year-old man presented with fever to another hospital in 2009 and subsequently developed lung metastasis that was managed with lobectomy, platinum-based chemotherapy, radiation, and autologous F IGURE 1 Morphologic findings.